Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting

Tags:   ASH  

CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data from two pipeline programs that modulate the hepcidin pathway will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually December 5-8, 2020.

Details of the presentations are as follows:

Abstract Number: 1690Title: DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low HepcidinDate: Sunday, December 6, 2020, 7:00 AM-3:30 PM ESTSession: 102. Regulation of Iron Metabolism: Poster IIPresenter: Vu Hong, PhD, Director and Project Leader

---

---

Abstract Number: 2599Title: DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Decreases Hepcidin and Increases Transferrin Saturation in a Non-Human Primate Model of Cytokine (IL-6) Induced HypoferremiaDate: Monday, December 7, 2020, 7:00 AM-3:30 PM ESTSession: 102. Regulation of Iron Metabolism: Poster IIIPresenter: Maria Beconi, PhD, SVP of Translational Research and Development

Full abstracts are currently available through the ASH conference website: www.hematology.org/Annual-Meeting/Abstracts/.

About Disc MedicineDisc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Currently focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

SOURCE Disc Medicine

http://www.discmedicine.com

More news releases in similar topics

Cision Distribution 888-776-0942 from 8 AM - 9 PM ET